Rhodin, Kristen E.
Farrow, Norma E.
Xu, Maria
Lee, Jay
Tyler, Douglas S.
Beasley, Georgia M.
Funding for this research was provided by:
NIH (1R38AI140297, K08 CA237726-01A1)
Article History
Received: 13 September 2022
Accepted: 3 January 2023
First Online: 15 January 2023
Disclosures
: Georgia Beasley has received clinical trial funding paid to Duke University from Delcath, Istari, Replimune, Oncosec, and Checkmate, and has served on a one-time advisory board for Cardinal Health and Regeneron. She is also supported by NIH K08 CA237726-01A1. Kristen E. Rhodin is supported by NIH 1R38AI140297. Norma E. Farrow, Maria Xu, Jay Lee, and Douglas S. Tyler have no disclosures to declare.